

AD-A078 480


NAVAL MEDICAL RESEARCH INST BETHESDA MD
DRUG INTERFERENCE WITH THE TRIHYDROXYINDOLE METHOD FOR FREE CAT--ETC(U)
SEP 79 L D MELL, A B GUSTAFSON , A R DASLER
NMRI-79-51

F/G 6/15


UNCLASSIFIED

NL

| OF |
AD
A078480



END
DATE
FILMED
1-80
DDC




MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS-1963-A

12

NAVAL MEDICAL RESEARCH INSTITUTE

BETHESDA, MARYLAND

ADA 078480



LEVEL II

DDC FILE COPY

79-51

DRUG INTERFERENCE WITH THE TRIHYDROXINDOLE
METHOD FOR FREE CATECHOLAMINES IN URINE

LD MELL Jr., AB GUSTAFSON, and AR DASLER

DDC
RECEIVED
DEC 26 1979
A

79-12 21 033

W. F. Miner, CAPT, MC, USN

Commanding Officer

Naval Medical Research Institute

NAVAL MEDICAL RESEARCH AND DEVELOPMENT COMMAND

Acknowledgment

This work was supported by the Naval Medical Research and Development Command, National Naval Medical Center, Department of the Navy, Research Task No. ZF51.524.023.1007. The opinions and statements contained herein are the private ones of the authors and are not to be construed as official or reflecting the views of the Navy Department or the Naval Service at large. We thank Drs. David E. Uddin and F. Lee Rodkey, of the Naval Medical Research Institute, for their advice.

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM	
1. REPORT NUMBER NMRI-79-51	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER	9
4. TITLE (and Subtitle) DRUG INTERFERENCE WITH THE TRIHYDROXYINDOLE METHOD FOR FREE CATECHOLAMINES IN URINE		5. TYPE OF REPORT & PERIOD COVERED Medical Research Progress Report	
7. AUTHOR(s) Leroy D./Mell, Jr., Anthony B./Gustafson, and Adolph R./Dasler		8. CONTRACT OR GRANT NUMBER(s) 16 F51524	
9. PERFORMING ORGANIZATION NAME AND ADDRESS Naval Medical Research Institute Bethesda, Maryland 20014		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS ZF51,524,023,1007 Report No. 8	
11. CONTROLLING OFFICE NAME AND ADDRESS Naval Medical Research and Development Command Bethesda, Maryland 20014		12. REPORT DATE September 1979	
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office) Bureau of Medicine and Surgery Department of the Navy Washington, D.C. 20372		13. NUMBER OF PAGES 17	
		15. SECURITY CLASS. (of this report) UNCLASSIFIED	
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE	
16. DISTRIBUTION STATEMENT (of this Report) Approved for public release and sale; distribution unlimited			
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)			
18. SUPPLEMENTARY NOTES			
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Trihydroxyindole, Fluorometric, Catecholamines			
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) Thirty-five of 108 drugs tested may interfere with the trihydroxyindole fluorometric method for urinary free catecholamines. Screening for inter- ference was accomplished by testing the total daily dose of a drug or portion thereof for possible fluorescence. Further information was obtained by adding a similar dose for each of 16 interfering drugs to 150 ml of fresh, pooled urine containing 67 ng/ml each of norepinephrine and epinephrine. Additional studies of seven interfering drugs were conducted using healthy males and			

DD FORM 1 JAN 73 1473

EDITION OF 1 NOV 68 IS OBSOLETE
S/N 0102-LF-014-6601

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

249 650

500

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

assaying catecholamines from 4-h urine specimens. Four possible modes of interference were observed: (1) substances which reacted to form fluorescent products, such as thiamine hydrochloride and ascorbic acid; (2) substances with native fluorescence, such as riboflavin; (3) substances which are intensely colored in solution and interfered with fluorescent excitation or emission spectra, such as phenazopyridine hydrochloride; and (4) substances which inhibited catecholamine extraction onto alumina, such as methenamine mandelate. This work has expanded upon data previously available in identifying drugs which may spuriously alter urinary free catecholamine excretion measured by the trihydroxyindole procedure.

Accession For	
DDIS GRMM	<input checked="" type="checkbox"/>
DDC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist.	Availand/or special
A	

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)

TABLE OF CONTENTS

	Page No.
Introduction	1
Materials & Methods	1
Apparatus	1
Reagents	1-2
Samples	2
Procedure	2-3
Drug Interference in Pooled Urine	3
<u>In Vivo</u> Drug Interference	3
Table 1	8-9
Table 2	10
Table 3	11
Table 4	12
Discussion	13-14
References	15-17

LIST OF FIGURES

	Page No.
Fig. 1. Fluorescent Spectra for Thiamine Hydrochloride and Tetracycline Hydrochloride During the Trihydroxyindole Procedure	4
Fig. 2. Fluorescent Spectra for Triamterene and Riboflavin in the Trihydroxyindole Procedure	5
Fig. 3. Fluorescent Spectra Obtained for Phenazopyridine Hydrochloride in Pooled Urine Analyzed by the Trihydroxyindole Procedure	6
Fig. 4. Some Selected Drug Interferences <u>In Vivo</u> with the Trihydroxyindole Method	7

INTRODUCTION

The quantitative determination of urinary free catecholamine excretion has been studied in both health and disease. Used to establish the presence of chromaffin cell tumors such as pheochromocytoma (1), studies of catecholamine excretion have also been examined in such diverse diseases as hypertension (2), diabetes mellitus (3), and muscular dystrophy (4). Catecholamine excretion has also been studied in acute stress situations such as myocardial infarction (5), thermal injury (6), and physical exertion under varying work loads (7) and environmental conditions (8,9). While recent work has improved the sensitivity of the trihydroxyindole fluorometric method by optimizing various analytical conditions such as pH and optimal excitation and emission wavelengths (10-16), corresponding emphasis has not been directed towards identifying substances which may interfere with the fluorometric method (17). Previous studies have discussed the specificity of the trihydroxyindole method (18,19) and identified several medications which spuriously elevate results due to native or developed fluorescence (20-24). Other drugs such as methenamine mandelate may yield falsely decreased results (25). Ideally, no drug should be administered during evaluation of catecholamine excretion; yet such circumstances are not always possible. Increased knowledge of drugs that may interfere with the trihydroxyindole fluorometric method is important to avoid distortion of results and diagnostic confusion (26). This study has examined 108 substances for such interference.

MATERIALS AND METHODS

Apparatus

Fluorescence spectra and relative fluorescence measurements were obtained using an Aminco-Bowman spectrofluorometer with models P416-992 xenon lamp and 10-222 solid state photomultiplier microphotometer (American Instrument Co., Silver Spring, MD 20910). "Biomed" mini-columns (1 cm i.d. X 18 cm; New England Nuclear, Worcester, Mass. 01608) were used for elution from alumina.

Reagents

Glass-distilled, de-ionized water was used for solutions. Standard solutions (1 mg/ml) of epinephrine and norepinephrine were prepared with 0.01 mol/liter hydrochloric acid. Working standards (1 µg/ml) were prepared prior to use by diluting 0.1 ml of standard to 100 ml with 0.01 mol/liter hydrochloric acid. Standard solutions were stored at 4°C for no longer than two weeks. Alumina (neutral, Brockman activity grade 1) was obtained from Sigma Chemical Co., St. Louis, Mo. 63178. Norepinephrine, epinephrine, caffeine, salicylic acid, uric acid, riboflavin and pyridoxine hydrochloride were obtained from Aldrich Chemical Co., Milwaukee, Wisc. 53233; trimethylamine, thiamine hydrochloride and nicotinic acid were obtained from Calbiochem, La Jolla, Calif. 92037. Minoxidil was supplied as a gift by Upjohn Company, Kalamazoo,

Mich. 49001. The remaining compounds were pharmaceuticals obtained from the Pharmacy Service, National Naval Medical Center, Bethesda, Md. 20014. Drugs were used as received.

Samples

Samples for screening were prepared by dissolving part or all of a total daily adult dose of a given compound in 150 ml of de-ionized, distilled water which was adjusted to pH 3 with 12 mol/liter hydrochloric acid and then analyzed. Further studies on interfering drugs were conducted by adding a similar dose of the specific substance to 150 ml of fresh, pooled urine adjusted to contain 10 μ g each of norepinephrine and epinephrine. Additional studies were conducted with healthy men taking a specified dose of a given compound for seven days during routine daily activity. Dietary substances known to interfere with the trihydroxyindole method were avoided. Four-hour urine specimens (0800 to 1200h) were collected on the last two days of drug administration, and analyzed immediately or stored at -35°C for no longer than 5 days. Two 4-h urines (0800 to 1200h) collected from each individual prior to drug administration and during routine daily activity served as control specimens.

Procedure

Fluorometric analysis of samples followed the procedure described in detail by Crout (27), including steps for alumina preparation. Catecholamines were extracted onto alumina from samples at pH 8.4 and eluted with 0.2 mol/liter acetic acid. Catecholamines in the alumina column eluate were converted to trihydroxyindole derivatives and assayed fluorometrically. In vivo studies were corrected to 100% recovery based on recovery determined for control solutions analyzed simultaneously.

After correcting for blank fluorescence if present, the relative intensity of observed fluorescence for an interfering substance was compared to fluorescence obtained for the 1 μ g/ml norepinephrine standard. This ratio defines a relative interference by percent and cannot be used to predict fluorescent interference in vivo. Substances were considered to exhibit moderate interference if this ratio was less than 10 percent of the fluorescence observed for the norepinephrine standard, and to exhibit strong interference if the ratio was greater than 10 percent.

Since the trihydroxyindole fluorophores are unstable, consistent blank preparation is necessary. The blank is formed by allowing the fluorescence developed by the sample to fade through oxidation of trihydroxyindole derivatives to non-fluorescing compounds. Therefore, an abnormal blank was defined as a blank differing from the norepinephrine standard blank, which is usually 10 percent of the fluorescent intensity of the norepinephrine standard (27).

RESULTS

The results for initial testing are presented in Tables 1, 2 and 3. For the 73 substances listed in Table 1 fluorescent spectra differed only slightly or not at all from the corresponding blank, and thus no interference would be expected with the trihydroxyindole procedure. Substances which exhibited fluorescent activity at the excitation and emission wavelengths used in the dihydroxyindole method for dopamine (28) are also noted. Twenty compounds are presented in Table 2 which exhibited moderate interference. Representative fluorescent spectra for drugs of this category are given in Figure 1. Fifteen substances exhibiting strong interference are listed in Table 3 with representative fluorescent spectra presented in Figures 2 and 3. The presence of an abnormal blank is noted in Tables 2 and 3.

Drug Interference in Pooled Urine

Apparent catecholamine recoveries from pooled urine for sixteen substances and three drug combinations or regimens that might be encountered in clinical practice are presented in Table 4. For substances such as triamterene, quinidine sulfate and chlorpromazine hydrochloride which yielded abnormal blanks, epinephrine values were not consistent with norepinephrine recoveries and both spuriously elevated and decreased results were obtained. Interfering drugs with normal blanks, such as ascorbic acid and thiamine hydrochloride, gave falsely elevated catecholamine recoveries. Other substances such as phenazopyridine hydrochloride and rifampin form intensely colored solutions during the trihydroxyindole procedure. These drugs have strong visible absorption at or near the fluorescent excitation maximum (410 nm) which greatly reduces fluorescent emission (Figure 3).

In Vivo Drug Interference

Apparent norepinephrine excretions in the presence of some common medications each administered orally to five healthy men are presented in Figure 4 with control data for each test subject. Reference values for 4-h urines (0800 - 1200 h) for 25 determinations from 11 other healthy male subjects during routine daily activity are presented as mean \pm 2 SD (shaded area). Each symbol in Figure 4 represents an average of two 4-h urine collections (0800 - 1200 h); the mean difference for norepinephrine excretion between the two control values obtained for each of the six participating individuals was 8 ng/min. With administration of ascorbic acid, thiamine hydrochloride or riboflavin, norepinephrine excretion appears to be spuriously elevated; mentenamine mandelate or phenazopyridine hydrochloride administration resulted in falsely decreased norepinephrine excretion. Triamterene (100 mg/d) was administered to two test subjects (AG, LM) using the same experimental protocol and apparent norepinephrine excretion was 75 and 25 ng/min, respectively. Two hypertensive males on chronic methyl dopa and diuretic therapy had apparent norepinephrine excretions of 290 and 445 ng/min based on two 4-h urine collections (0800 - 1200 h) for each individual.




Fig. 1. Fluorescent Spectra for Thiamine Hydrochloride and Tetracycline Hydrochloride During the Trihydroxyindole Procedure. Fifty mg of thiamine hydrochloride (curve a), 250 mg of tetracycline hydrochloride (curve b), or 0.2 ml of 1 μ g/ml norepinephrine standard (curve c) were added to 150 ml of acidified, distilled water and extracted with alumina at pH 8.4. Two hundred μ l of the respective column eluates were analyzed by the trihydroxyindole procedure. Blanks are indicated by dashed lines. Excitation wavelength was 410 nm.




Fig. 2. Fluorescent Spectra for Triamterene and Riboflavin in the Trihydroxyindole Procedure. One hundred mg of triamterene (curve a) or 50 mg of riboflavin (curve b) were treated as described in Figure 1. Dashed lines represent sample blanks.




Fig. 5. Fluorescent Spectra Obtained for Phenazopyridine Hydrochloride in Pooled Urine Analyzed by the Trihydroxyindole Procedure. Curves a and b are the respective fluorescent spectra for 200 μ l and 100 μ l aliquots of the column eluate obtained from alumina extraction of 150 ml of pooled urine containing 67 ng/ml each of norepinephrine and epinephrine to which 150 mg of phenazopyridine hydrochloride had been added. Curve c is the spectrum obtained for a 100 μ l aliquot of a 1.0 μ g/ml norepinephrine standard. Sample blanks are indicated by dashed lines; excitation wavelength was 410 nm.




Fig. 4. Some Selected Drug Interferences In Vivo with the Trihydroindole Method. Apparent norepinephrine excretion in ng/min was determined for five healthy males taking each of five selected medications for seven days during routine activity. Each symbol represents an individual and is the mean value from two 4-h urine specimens (0800 to 1200 h) collected prior to (control), and on the last two days of each drug administration. The shaded area represents the mean ± 2 SD (40 ± 20 ng/min) for 25 determinations of norepinephrine from 11 other healthy males under similar control conditions. The total dose of a drug is expressed in parentheses with administration by mouth as follows: thiamine hydrochloride 100 mg daily in AM, ascorbic acid 500 mg every 6 h, riboflavin 10 mg daily in AM, methenamine mandelate 500 mg every 6 h, and phenazopyridine hydrochloride 100 mg every 8 h.

TABLE 1. Substances Exhibiting No Fluorescence During In Vitro Testing with Trihydroxyindole Procedure^a

Acetaminophen (325)	<u>Brondecon</u> [Warner/Chilcott]:
Acetazolamide (500)	Glyceryl guaiacolate (400)
Acetohexamide (250)	Oxtriphylline (800)
Acetylsalicylic acid ^b (325)	Caffeine (200)
<u>Actifed</u> [Burroughs Wellcome]:	Chlordiazepoxide hydrochloride (10)
Pseudoephedrine hydrochloride (60)	Chlorpheniramine maleate (4.0)
Triprolidine hydrochloride (2.5)	Chlorpropamide (125)
Allopurinol (50)	Choline chloride (10)
Aminophylline (200)	Chromolyn sodium (20)
<u>Anacin</u> [Whitehall]:	Clofibrate (500)
Acetylsalicylic acid (800)	Clonidine hydrochloride (0.2)
Caffeine (64)	Colchicine (0.325)
APC ^b	Contac [Menley & James]:
Acetylsalicylic acid (230)	Beoladonna alkaloids (0.2)
Caffeine (32)	Chlorpheniramine maleate (4.0)
Phenacetin (170)	Phenylpropanolamine hydrochloride (50)
Biotin (5.0)	Dextroamphetamine sulfate (5.0)
Diazepam (10)	<u>Lomotil</u> [Searle & Co.]:
Diazoxide (300)	Atropine sulfate (0.05)
Dimenhydrinate (25)	Diphenoxylate hydrochloride (5.0)
Diphenylhydantoin sodium (100)	Medroxyprogesterone acetate (10)
Ephedrine sulfate (50)	Methenamine (500)
Ethacrynic acid (100)	Methylprednisolone sodium succinate (125)
Ethanol (80)	3-Methylxanthine (500)
<u>Excedrin</u> [Bristol-Myers]:	Minoxidil (10)
Acetaminophen (97)	Morphine sulfate (10)
Acetylsalicylic acid (194)	Nalidixic acid (500)
Caffeine (65)	Nicotinic acid (10)
Salicylamide (129)	Nitroglycerin (0.4)
Fenfluramine hydrochloride (20)	<u>Ornade</u> [Smith Kline & French]:
Flurazepam hydrochloride (30)	Chlorpheniramine maleate (8.0)
Furosemide (40)	Isopropamide (2.5)
Haloperidol (1.0)	Phenylpropanolamine hydrochloride (50)
Hydralazine hydrochloride (50)	Oxazepam (30)
Hydrochlorothiazide (100)	Panthenic acid (10)
Hydroxyzine hydrochloride (25)	Penicillin potassium phenoxy-methyl (500)
Indomethacin (25)	Phenformin hydrochloride (25)
Insulin isophane (40 units)	Phenobarbital (64)
Insulin protamine zinc (40 units)	
Levothroxine sodium (0.05)	

^aDose tested in parentheses following each substance is expressed in mg or as noted.

^bpossible interference with urinary free dopamine assay: $\lambda_{ex} = 320 \text{ nm}$, $\lambda_{em} = 375 \text{ nm}$.

TABLE 2. Substances Exhibiting Moderate Fluorescence During In Vitro Testing with the Trihydroxyindole Procedure^a

<u>Aldactazide</u> [Searle & Co.]:	Droxoral [Schering]:
Hydrochlorothiazide (25)	Dexbrompheniramine maleate (6)
Spironolactone (25)	<u>d</u> -Isoephedrine sulfate (120)
Chlorthalidone (100)	Estrogens, conjugated (0.31)
Cholestyramine resin (4000)	Erythromycin stearate (500)
Codeine sulfate (32)	Glyceryl guaiacolate (100)
Dantrolene sodium (50)	Hydrochlorothiazide (100)
Digoxin (0.06)	Meprobamate (400)
<u>Dimetapp</u> ^{b,c} [Robbins]:	Propoxyphene hydrochloride (65)
Brompheniramine maleate (24)	Quinine sulfate ^c (324)
Phenylephrine hydrochloride (30)	Reserpine (0125)
Phenylpropanolamine hydrochloride (30)	Tetracycline hydrochloride ^c (250)
Diphenhydramine hydrochloride ^{b,c} (50)	Thiamine hydrochloride (50)
	Tolbutamide (250)

^aDose tested in parentheses following each substance is expressed in mg.

^bPossible interference with urinary free dopamine assay: $\lambda_{ex} = 320 \text{ nm}$, $\lambda_{em} = 375 \text{ nm}$.

^cAbnormal blank.

TABLE 3. Substances Exhibiting Strong Fluorescence During In Vitro Testing with the Trihydroxyindole Method^a

Ampicillin (250)	Methenamine mandelate (1000)
Ascorbic acid ^b (500)	Methyldopa (250)
Chlorpromazine hydrochloride ^{b,c} (25)	Nitrofurantoin ^c (100)
<u>Dyazide</u> ^c [Smith Kline & French]:	Phenazopyridine hydrochloride ^{b,c} (100)
Hydrochlorothiazide (25)	Phenylbutazone ^c (25)
Triamterene (50)	Quinidine sulfate ^c (400)
Formaldehyde (1.0)	Riboflavin ^{b,c} (50)
Isoproterenol hydrochloride ^c (10)	Rifampin ^{b,c} (300)
	Triamterene ^c (100)

^aDose tested in parentheses following each substance is expressed in mg.

^bPossible interference with urinary free dopamine assay: $\lambda_{ex} = 320 \text{ nm}$, $\lambda_{em} = 375 \text{ nm}$.

^cAbnormal blank.

TABLE 4. Apparent Catecholamine Values from Pooled Urine in the Presence of Substances Interfering with the Trihydroxyindole Method^a

Drug(s) ^b	ug Catecholamine ^c	
	Norepinephrine	Epinephrine
Ampicillin (250)	20.4	12.0
Ascorbic acid (500)	13.4	13.0
Chlorpromazine hydrochloride (25)	14.3	4.1
<u>Dyazide</u> ^e	d	15.9
Erythromycin stearate (500)	12.0	13.4
Formaldehyde (1.0)	2.2	d
Isoproterenol hydrochloride (10)	d	24.1
Methenamine mandelate (1000)	5.5	1.7
Methyldopa (500)	49.0	28.0
Phenazopyridine hydrochloride (100)	12.0	d
Phenylbutazone (25)	16.0	9.1
Quinidine sulfate (400)	17.0	7.8
Riboflavin (10)	1.4	0.2
Rifampin (200)	5.6	7.5
Thiamine hydrochloride (50)	12.5	11.7
Triamterene (100)	d	10.4
Ascorbic acid (500) —	3.2	0.7
Methenamine mandelate (1000) —		
<u>Dyazide</u> ^e —	23.0	12.0
Methyldopa (100) —		
<u>Dyazide</u> ^e —		
Riboflavin (10) —	d	d
Thiamine Hydrochloride (10) —		

^aEach drug was added to 150 ml of pooled urine adjusted to contain 10 µg each of norepinephrine and epinephrine. Dose tested in mg is in parentheses following each substance.

^bDrugs studied in combination indicated by bracket.

^cAdjusted to 100% recovery.

^dNegative result obtained.

^eDyazide [Smith Kline & French]: Hydrochlorothiazide (25), triamterene (50).

DISCUSSION

There are several modes by which drugs may interfere with the trihydroxyindole method. One such mechanism involves drugs such as methyl dopa which react to yield fluorescent products. Similar in structure to the biogenic amines, the trihydroxyindole derivatives of these drugs will fluoresce at the emission wavelengths used for norepinephrine and epinephrine determinations yielding spuriously elevated results. Other examples of similar interference include thiamine hydrochloride which may be oxidatively converted to highly fluorescent thiochrome in alkaline solution (29) as seen in Figure 1 and ascorbic acid which, in addition to its antioxidant property, may cause in high concentration formation of fluorescent complexes (30). Both vitamins may cause false elevation of catecholamine excretion as illustrated in Table 4 and Figure 4.

Another apparent mode of interference is provided by formaldehyde, a metabolic breakdown product of methenamine mandelate in urine. Formaldehyde inhibits the recovery of catecholamines during alumina extraction, and may even depress the formation of trihydroxyindole derivatives (24). Such inhibition of extraction onto alumina spuriously decreases apparent catecholamine excretion as seen in Table 4 and Figure 4. A third possible mode of interference is caused by substances such as phenazopyridine hydrochloride and rifampin which in solution form an intense color not removed during alumina extraction, which interferes with fluorescent excitation and emission spectra. These substances exhibit strong absorption near the excitation wavelength maximum (410 nm) used in the trihydroxyindole method, and as seen in Figure 3 for phenazopyridine hydrochloride, will diminish the fluorescent intensity of the trihydroxyindole derivatives in relative proportion to amount of drug present. Such interference usually decreases apparent catecholamine values illustrated by Table 4 and Figure 4.

Substances with native fluorescence such as riboflavin may also interfere. Unfortunately such fluorescence is present in both blank and sample specimens, and determination of catecholamines is altered in unpredictable fashion depending on the relative fluorescence of sample and blank. If the interfering fluorescence contributes to a greater extent in the blank solution than the test solution, a low or negative value for apparent norepinephrine excretion may be obtained (Figure 2). Conversely, if such fluorescence contributes predominately to the test solution an elevated apparent norepinephrine excretion may result. Clearly catecholamine determinations by the trihydroxyindole method in the presence of such interference are meaningless even if they are apparently normal. As an example, riboflavin appears to decrease catecholamine values in vitro (Table 4), yet in vivo data of Figure 4 indicate no change or perhaps an increase in apparent norepinephrine excretion. Similar inconsistent results from Table 4 are obtained for quinidine sulfate, chlorpromazine hydrochloride and phenylbutazone.

Other substances interfering in similar fashion include triamterene whose emission spectrum is presented in Figure 2 and whose presence in pooled

urine (Table 4) decreased apparent norepinephrine recovery, yet in vivo studies of triamterene administration in two individuals resulted in both elevated and decreased apparent norepinephrine excretion. Another example of this type of interference is tetracycline hydrochloride (Figure 1). Presumably other drugs identified in Tables 2 and 3 yielding abnormal blanks may also interfere with the trihydroxyindole method in similar fashion. In most cases, such interference can be identified during fluorometric analysis by observing whether the blank is higher than normally obtained.

Several drug regimens that might be encountered in clinical practice were examined for interference in pooled urine. Each of the three combinations presented in Table 4 might interfere in two different modes with the trihydroxyindole method, and the inconsistent behavior of such interferences is illustrated by the data for Dyazide (Smith Kline & French), and methyldopa (Aldomet, Merck Sharp & Dohme) where norepinephrine concentration is spuriously doubled while epinephrine concentration is apparently unchanged.

The results of this paper should be interpreted with the view that while the kidney may excrete a substance unchanged, it is more likely to be excreted both intact and as a variety of metabolic breakdown products, all of which may vary considerably in their fluorometric activity or interaction with the trihydroxyindole method. This study has examined only a few metabolic products such as 3-methylxanthine and trimethylamine, formed from caffeine and choline chloride, respectively. In vivo data as in Figure 4 may also be influenced by variability in drug metabolism among different individuals, by concentration of the substance in urine, and by possible direct action of the drug upon catecholamine metabolism. Further, norepinephrine excretion may be directly influenced by glomerular filtration rate and urine pH (31). Ascorbic acid, riboflavin, and thiamine hydrochloride apparently do not affect urinary free norepinephrine excretion measured by reverse-phase high-pressure liquid chromatography (32).

In summary, this study has expanded upon data previously available in identifying drugs which may spuriously increase or decrease urinary free catecholamine excretion measured by the trihydroxyindole fluorometric method, and has illustrated and discussed several modes of such interference. A careful patient history should be obtained, and inconsistent or abnormal results must be verified by careful examination of the blank and sample fluorescent spectra in question so that drug-induced interferences may be avoided.

REFERENCES

1. Sjoerdsma, A., Engelman, K., Waldmann, T.A., Cooperman, L.H., and Hammond, W.G., Pheochromocytoma: Current concepts of diagnosis and treatment. Ann. Intern. Med. 65, 1302 (1966).
2. Nestel, P.J., and Esler, M.D., Patterns of catecholamine excretion in urine in hypertension. Circ. Res. 26: Suppl. II 75, (1970).
3. Abdel-Aziz, M.T., Abdel-Kader, M.M., and Rashad, M.M., Urinary catecholamines and their metabolites in diabetes. Acta Biol. Med. Ger. 34, 1643 (1975).
4. Mendell, J.R., Murphy, D.L., Engel, W.K., Chase, T.N., and Gordon, E., Catecholamines and indoleamines in patients with Duchenne muscular dystrophy. Arch. Neurol. 27, 518 (1972).
5. Januszewicz, W., Sznajderman, M., Wocial, B., and Preibisz, J., Urinary excretion of free norepinephrine and free epinephrine in patients with acute myocardial infarction in relation to its clinical course. Am. Heart J. 76, 345 (1968).
6. Wilmore, D.W., Long, J.M., Mason, A.D., Jr., Skreen, R.W., and Pruitt, B.A., Jr., Catecholamines: Mediator of the hypermetabolic response to thermal injury. Ann. Surg. 180, 653 (1974).
7. Cronan, T.L., and Howley, E.T., The effect of training on epinephrine and norepinephrine excretion. Med. Sci. Sports 6, 122 (1974).
8. Huikko, M., Jouppila, P., and Karki, N.T., Effect of Finnish bath (Sauna) on the urinary excretion of noradrenaline, adrenaline and 3-methoxy-4-hydroxy-mandelic acid. Acta Physiol. Scand. 68, 316 (1966).
9. Feller, R.P., and Hale, H.B., Human urinary catecholamines in relation to climate. J. Appl. Physiol. 19, 37 (1964).
10. Laverty, R., and Taylor, K.M., The fluorometric assay of catecholamines and related compounds: Improvements and extensions of the hydroxyindole technique. Anal. Biochem. 22, 269 (1968).
11. O'Hanlon, J.F., Jr., Campuzano, H.C., and Horvath, S.M., A fluorometric assay for subnanogram concentrations of adrenaline and noradrenaline in plasma. Anal. Biochem. 34, 568 (1970).
12. Anderson, B., Hovmoller, S., Karlsson, C., and Svensson, S., Analysis of urinary catecholamines: an improved auto-analyzer fluorescence method. Clin. Chim. Acta 58, 13 (1974).

13. Campuzano, H.C., Wilkerson, J.E., and Horvath, S.M., Fluorometric analysis of epinephrine. Anal. Biochem. 64, 578 (1975).
14. Quek, E.S.C., Buttery, J.E., and DeWitt, G.F., Catecholamines in urine: An evaluation of alumina-trihydroxyindole methods and a description of an improved method. Clin. Chim. Acta 58, 137 (1975).
15. Renzini, V., Brunori, C.A., and Volori, C., A sensitive and specific fluorometric method for the determination of noradrenalin and adrenalin in human plasma. Clin. Chim. Acta 30, 587 (1970).
16. Jiang, N., Machacek, D., and Wadel, O.P., Further study on the two-column plasma catecholamine assay. Mayo Clin Proc. 51, 112 (1976).
17. Young, D.S., Pestaner, L.C., and Gibberman, V., Effects of drugs on clinical laboratory tests. Clin. Chem. 21, 275D (1975).
18. Jacobs, S.L., Sobel, C., and Henry, R.J., Specificity of the THI method for determination of urinary catecholamines. J. Clin. Endocrinol. Metab. 21, 305 (1961).
19. Anton, A.H., and Sayre, D.F., A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J. Pharmacol. Exp. Ther. 138, 360 (1962).
20. von Euler, U.S., Sympatho-adrenal activity in physical exercise. Med. Sci. Sports 6, 165 (1974).
21. Carruthers, M., Conway, N., Taggart, P., Bates, D., and Somerville, W., Validity of plasma-catecholamine estimations. Lancet ii, 62 (1970).
22. Cross, F.C., Canada, A.J., and Davis, N.M., The affects of certain drugs on the results of some common laboratory diagnostic procedures. Am. J. Hosp. Pharm. 23, 234 (1966).
23. Elking, M.P., and Kabat, H.F., Drug induced modifications of laboratory test values. Am. J. Hosp. Pharm. 25, 485 (1968).
24. Blumberg, A.G., Heaton, A.M., and Vassiliades, J., The interference of chlorpromazine metabolites in the analysis of urinary methoxy-catecholamines. Clin. Chem. 12, 803 (1966).
25. Klotz, M.O., Rechter, H., and Meuffels, G., Interference by formaldehyde-forming drugs in the determination of urinary catecholamines. Clin. Chem. 10, 372 (1964).
26. Sapira, J.D., Klaniecki, T., and Ratkin, G., "Non-pheochromocytoma", JAMA 212, 2243 (1970).
27. Crout, J.R., Catecholamines in urine. Stand. Methods Clin. Chem. 3, 62 (1961).
28. Bischoff, F., and Torres, A., Determination of urine dopamine. Clin. Chem. 8, 370 (1962).

29. Henry, R.J., Cannon, O.C., and Winkelman, J.W., Clinical Chemistry: Principles and Techniques, 2nd ed., Hoeber, New York, N.Y., 1974, p 1371.

30. Weil-Malherbe, H., The fluorimetric estimation of catecholamines. Methods Med. Res. 9, 130 (1961).

31. Hollister, L.E., and Moore, F., Factors affecting excretion of catecholamines in man: Urine flow, urine pH and creatinine clearance. Res. Commun. Chem. Pathol. Pharmacol. 1, 193 (1970).

32. Mell, L.D., and Gustafson, A.B., Urinary free norepinephrine and dopamine determined by reverse-phase high-pressure liquid chromatography. Clin. Chem. 23, 473 (1977).